Department of Radiotherapy and Radio-Oncology at the University Hospital Salzburg, Landeskrankenhaus, Paracelsus Medical University, 5020, Salzburg, Austria.
Institute for Research and Development on Advanced Radiation Technologies (radART), Paracelsus Medical University, 5020, Salzburg, Austria.
Radiat Oncol. 2018 Feb 6;13(1):20. doi: 10.1186/s13014-018-0953-x.
To date, patients with glioblastoma still have a bad median overall survival rate despite radiation dose-escalation and combined modality treatment. Neurocognitive decline is a crucial adverse event which may be linked to high doses to the cortex. In a planning study, we investigated the impact of dose constraints to the cerebral cortex and its relation to the organs at risk for glioblastoma patients.
Cortical sparing was implemented into the optimization process for two planning approaches: classical intensity-modulated radiotherapy (IMRT) and robust treatment planning. The plans with and without objectives for cortex sparing where compared based on dose-volume histograms (DVH) data of the main organs at risk. Additionally the cortex volume above a critical threshold of 28.6 Gy was elaborated. Furthermore, IMRT plans were compared with robust treatment plans regarding potential cortex sparing.
Cortical dose constraints result in a statistically significant reduced cerebral cortex volume above 28.6 Gy without negative effects to the surrounding organs at risk independently of the optimization technique. For IMRT we found a mean volume reduction of doses beyond the threshold of 19%, and 16% for robust treatment planning, respectively. Robust plans delivered sharper dose gradients around the target volume in an order of 3 - 6%. Aside from that the integration of cortical sparing into the optimization process has the potential to reduce the dose around the target volume (4 - 8%).
We were able to show that dose to the cerebral cortex can be significantly reduced both with robust treatment planning and IMRT while maintaining clinically adequate target coverage and without corrupting any organ at risk. Robust treatment plans delivered more conformal plans compared to IMRT and were superior in regards to cortical sparing.
迄今为止,尽管采用了放疗剂量递增和联合治疗模式,胶质母细胞瘤患者的中位总生存期仍然较差。神经认知能力下降是一个关键的不良事件,可能与大脑皮质的高剂量有关。在一项计划研究中,我们研究了大脑皮质剂量限制对胶质母细胞瘤患者的影响及其与危险器官的关系。
在两种计划方法的优化过程中实施了皮质保护:经典调强放疗(IMRT)和稳健治疗计划。比较了具有和不具有皮质保护目标的计划,基于主要危险器官的剂量体积直方图(DVH)数据。此外,还详细阐述了超过 28.6Gy 临界阈值的皮质体积。此外,还比较了 IMRT 计划和稳健治疗计划在潜在皮质保护方面的差异。
皮质剂量限制导致大脑皮质体积在 28.6Gy 以上显著减少,而不影响周围的危险器官,独立于优化技术。对于 IMRT,我们发现超过阈值的剂量的平均体积减少了 19%,对于稳健治疗计划则减少了 16%。稳健计划在靶区周围产生了更陡峭的剂量梯度,约为 3-6%。除此之外,将皮质保护纳入优化过程具有降低靶区周围剂量的潜力(4-8%)。
我们能够表明,无论是使用稳健治疗计划还是 IMRT,都可以显著降低大脑皮质的剂量,同时保持临床充分的靶区覆盖,而不会损害任何危险器官。与 IMRT 相比,稳健治疗计划提供了更适形的计划,并且在皮质保护方面更具优势。